Antimycotic activity and in-silico validation of bioactive compounds of Roccella montagnei Bél. against clinically isolated onychomycosis fungus Trichophyton mentagrophytes (C.P. Robin) Sabour

Abstract

Dermatophytes are the most common slow growing contagious agents of cutaneous mycosis and persist as a significant public health issues despite of the availability of a number of antifungal medications. Trichophyton mentagrophytes (C.P. Robin) Sabour. is one of the fungal species which influences the dermatophytic diseases. A wide range of clinical dermatophytosis could infect scalp, face, hand, fingernails, toenails, feet, and also produce jock itch and ring worm of the body. Generally, terbinafine, is used to treat dermatophytosis induced by Trichophyton species. In most of the cases, synthetic anti-mycotic drugs fail over time resulting in development of resistant strains. Sustainable use of herbal sources has been recognised as novel therapeutic drugs to treat dermatophytic disorders. However, few reports are available on antimycotic activity of lichen species. Therefore, in this study, lichen species such as Roccella montagnei Bél was collected from prime locality of Bhubaneswar, Odisha. Antifungal potency of ethanol and methanol extractives of R. montagnei was screened by disc diffusion method against the clinical isolates of T. Mentagrophytes and standard deviation and error was calculated. The overall study resulted with a positive output and validated through in-silico database. Hence the entire study is based on biomedical evaluation and sustainable use of natural plant supplements for the benefit of human society.

Keywords

• Antifungal activity
• Dermatophytosis
• in-silico
• Trichophyton mentagrophytes

References

1. J. Intra, C. Sarto, S. Mazzola, C. Fania, N. Tiberti, P. Brambilla, “In vitro activity of antifungal drugs against Trichophyton rubrum and Trichophyton mentagrophytes spp. by E-test method and non-supplemented Mueller–Hinton agar plates,” Mycopathologia, Vol.184, pp. 517-523, 2019.
2. J. Roana, N. Mandras, D. Scalas, P. Campagna, V. Tullio, “Antifungal activity of Melaleuca alternifolia essential oil (TTO) and its synergy with itraconazole or ketoconazole against Trichophyton rubrum,” Molecules, Vol. 26(2), pp. 461, 2021.
3. T. Mishra, S. Shukla, S. Meena, R. Singh, M. Pal, D. K. Upreti, D. Datta, “Isolation and identification of cytotoxic compounds from a fruticose lichen Roccella montagnei, and it’s in silico docking study against CDK-10,” Revista Brasileira de Farmacognosia, pp. 724-728, 2017.
4. S. Dubale, D. Kebebe, A. Zeynudin, N. Abdissa, S. Suleman, “Phytochemical screening and antimicrobial activity evaluation of selected medicinal plants in Ethiopia,” Journal of Experimental Pharmacology, pp. 51-62, 2023.
5. Roccella montagnei Bél. Index Fungorum last access 08.08.2024
6. Trichophyton mentagrophytes (C.P. Robin) Sabour. Index Fungorum last access 08.08.2024
7. S. Z. Khader, S. S. Ahmed, T. Arunachalam, S. Nayaka, S. K. Balasubramanian, S. T. SyedAmeen, P. Ponnusamy, “Radical scavenging potential, antiinflammatory and antiarthritic activity of isolated isomer Methyl-γ-Orsellinate and roccellatol from Roccella montagnei Bel.” Bulletin of Faculty of Pharmacy, Cairo University, Vol. 56(1), pp. 39-45, 2018.
8. U.V. Mallavadhani, A.V. Sudhakar, “Roccellatol, a new β-orcinol based metabolite from the lichen Roccella montagnei,” Natural Product Research, Vol. 32(3), pp. 268-274, 2018.

9. V. B. Tatipamula, G. S. Vedula, A. V. Sastry, “Chemical and pharmacological evaluation of manglicolous lichen Roccella montagnei Bel em. DD Awasthi.” Future Journal of Pharmaceutical Sciences, Vol. 5 pp. 1-9, 2019.
10. N. S. Vsdna, M. Muniappan, I. Kannan, S. Viswanathan, “Phytochemical analysis and docking study of compounds present in a polyherbal preparation used in the treatment of dermatophytosis,” Current Medical Mycology, Vol. 3(4), pp. 6, 2017.
11. N. Hassan, M. Singh, S. Sulaiman, P. Jain, K. Sharma, S. Nandy, M. Dudeja, A. Ali, Z. Iqbal, “Molecular docking-guided ungual drug-delivery design for amelioration of onychomycosis,” ACS Omega, Vol. 4(5), pp. 9583-9592, 2019.
12. P. Dixit, A. Maurya, T. Mishra, D.K. Upreti, and M. Pal, “Evaluation of Phytochemical Constituents and Antioxidant activity of the Roccella montagnei”, Cryptogam Biodiversity and Assessment, vol. 2(1), pp. 14-18, 2017.
13. S. Kim, P.A. Thiessen, E.E. Bolton, J. Chen, G. Fu, A. Gindulyte and S.H. Bryant, “PubChem substance and compound databases”, Nucleic Acids Research, 44(D1), D1202-D1213, 2016.
14. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig and P.E. Bourne, “The protein data bank”, Nucleic Acids Research, 28(1), pp. 235-242, 2000.
15. X. Chen, H. Li, L. Tian, Q. Li, J. Luo and Y. Zhang, “Analysis of the physicochemical properties of acaricides based on Lipinski's rule of five”, Journal of Computational Biology, vol. 27(9), pp. 1397-1406, 2020.
16. Z.J. Yao, J. Dong, Y.J. Che, M.F. Zhu, M. Wen, N.N. Wang, and D.S. Cao, “TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR models”, Journal of Computer-aided Molecular Design, vol. 30, pp. 413-424, 2016.
17. R. Kiss, M. Sandor and F.A. Szalai, http://Mcule. com: a public web service for drug discovery, Journal of Cheminformatics, 4(Suppl 1), P17, 2012.
18. UniProt Consortium, T. “UniProt: the universal protein knowledgebase”, Nucleic Acids Research, vol. 46(5), pp. 2699-2699, 2018.
19. A.B. Macura, “In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods”, International Journal of Dermatology, vol. 32(7), pp. 533-536, 1993.
20. H.F. Chambers, “Community-associated MRSA—resistance and virulence converge”, New England Journal of Medicine, vol. 352(14), pp. 1485-1487, 2005.
21. M. Giri and S. Parida, “Phytochemical inhibitors from Leucas aspera against the target proteins induced by Trichophyton mentagrophytes using computational techniques”, Journal of Basic Microbiology, e202400112. 2024.